Marked heterogeneity of aromatase activity in human malignant melanoma tissue

R. J. Santen, S. J. Santner, Harold Harvey, Allan Lipton, M. Simmonds, P. D. Feil, E. Manders, T. S. Davis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The prognosis from human malignant melanoma varies according to sex and to multiple histologic, biologic and cell kinetic parameters. Thus melanomas exhibit a major degree of heterogeneity in their biologic properties and further characterization of their biochemical heterogeneity should yield important information. The present study sought to demonstrate the activity of a biochemical marker of estrogen synthesis, the aromatase enzyme, in melanoma tissue and to determine its range of activity. Initially, we validated a highly sensitive radiometric assay for aromatase by comparing it with a direct product isolation method. We detected production of 417 pmol/g protein/h of estrone and 37.3 pmol/g protein/h of estradiol by direct product isolation in a human melanoma and 398 pmol estrone/g protein/h by the radiometric assay. The activity present was blocked by similar amounts of the aromatase inhibitor, aminoglutethimide, as were necessary to block placental, breast cancer, and rat brain aromatase activity. We then assayed aromatase radiometrically in 19 human melanomas and found measurable activity ranging from 9 to 398 pmol estrone/g protein/h in 15 tissues. No relationship with the patient's age or sex was demonstrated. The activity exceeded by 2-fold that previously detected in 49 61 human breast cancers. This study identified a marker enzyme in melanoma tissue which varied by 40-fold among human tumors. Correlation of aromatase activity with prognosis and response to various types of therapy is now necessary to establish the biologic relevance of this finding.

Original languageEnglish (US)
Pages (from-to)1811-1816
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume24
Issue number12
DOIs
StatePublished - Jan 1 1988

Fingerprint

Aromatase
Human Activities
Melanoma
Estrone
Proteins
Aminoglutethimide
Breast Neoplasms
Aromatase Inhibitors
Enzymes
Brain Neoplasms
Estradiol
Estrogens
Biomarkers
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Santen, R. J. ; Santner, S. J. ; Harvey, Harold ; Lipton, Allan ; Simmonds, M. ; Feil, P. D. ; Manders, E. ; Davis, T. S. / Marked heterogeneity of aromatase activity in human malignant melanoma tissue. In: European Journal of Cancer and Clinical Oncology. 1988 ; Vol. 24, No. 12. pp. 1811-1816.
@article{e5bc53167a404ab88f4b4801adb36959,
title = "Marked heterogeneity of aromatase activity in human malignant melanoma tissue",
abstract = "The prognosis from human malignant melanoma varies according to sex and to multiple histologic, biologic and cell kinetic parameters. Thus melanomas exhibit a major degree of heterogeneity in their biologic properties and further characterization of their biochemical heterogeneity should yield important information. The present study sought to demonstrate the activity of a biochemical marker of estrogen synthesis, the aromatase enzyme, in melanoma tissue and to determine its range of activity. Initially, we validated a highly sensitive radiometric assay for aromatase by comparing it with a direct product isolation method. We detected production of 417 pmol/g protein/h of estrone and 37.3 pmol/g protein/h of estradiol by direct product isolation in a human melanoma and 398 pmol estrone/g protein/h by the radiometric assay. The activity present was blocked by similar amounts of the aromatase inhibitor, aminoglutethimide, as were necessary to block placental, breast cancer, and rat brain aromatase activity. We then assayed aromatase radiometrically in 19 human melanomas and found measurable activity ranging from 9 to 398 pmol estrone/g protein/h in 15 tissues. No relationship with the patient's age or sex was demonstrated. The activity exceeded by 2-fold that previously detected in 49 61 human breast cancers. This study identified a marker enzyme in melanoma tissue which varied by 40-fold among human tumors. Correlation of aromatase activity with prognosis and response to various types of therapy is now necessary to establish the biologic relevance of this finding.",
author = "Santen, {R. J.} and Santner, {S. J.} and Harold Harvey and Allan Lipton and M. Simmonds and Feil, {P. D.} and E. Manders and Davis, {T. S.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/0277-5379(88)90090-9",
language = "English (US)",
volume = "24",
pages = "1811--1816",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "12",

}

Santen, RJ, Santner, SJ, Harvey, H, Lipton, A, Simmonds, M, Feil, PD, Manders, E & Davis, TS 1988, 'Marked heterogeneity of aromatase activity in human malignant melanoma tissue', European Journal of Cancer and Clinical Oncology, vol. 24, no. 12, pp. 1811-1816. https://doi.org/10.1016/0277-5379(88)90090-9

Marked heterogeneity of aromatase activity in human malignant melanoma tissue. / Santen, R. J.; Santner, S. J.; Harvey, Harold; Lipton, Allan; Simmonds, M.; Feil, P. D.; Manders, E.; Davis, T. S.

In: European Journal of Cancer and Clinical Oncology, Vol. 24, No. 12, 01.01.1988, p. 1811-1816.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Marked heterogeneity of aromatase activity in human malignant melanoma tissue

AU - Santen, R. J.

AU - Santner, S. J.

AU - Harvey, Harold

AU - Lipton, Allan

AU - Simmonds, M.

AU - Feil, P. D.

AU - Manders, E.

AU - Davis, T. S.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The prognosis from human malignant melanoma varies according to sex and to multiple histologic, biologic and cell kinetic parameters. Thus melanomas exhibit a major degree of heterogeneity in their biologic properties and further characterization of their biochemical heterogeneity should yield important information. The present study sought to demonstrate the activity of a biochemical marker of estrogen synthesis, the aromatase enzyme, in melanoma tissue and to determine its range of activity. Initially, we validated a highly sensitive radiometric assay for aromatase by comparing it with a direct product isolation method. We detected production of 417 pmol/g protein/h of estrone and 37.3 pmol/g protein/h of estradiol by direct product isolation in a human melanoma and 398 pmol estrone/g protein/h by the radiometric assay. The activity present was blocked by similar amounts of the aromatase inhibitor, aminoglutethimide, as were necessary to block placental, breast cancer, and rat brain aromatase activity. We then assayed aromatase radiometrically in 19 human melanomas and found measurable activity ranging from 9 to 398 pmol estrone/g protein/h in 15 tissues. No relationship with the patient's age or sex was demonstrated. The activity exceeded by 2-fold that previously detected in 49 61 human breast cancers. This study identified a marker enzyme in melanoma tissue which varied by 40-fold among human tumors. Correlation of aromatase activity with prognosis and response to various types of therapy is now necessary to establish the biologic relevance of this finding.

AB - The prognosis from human malignant melanoma varies according to sex and to multiple histologic, biologic and cell kinetic parameters. Thus melanomas exhibit a major degree of heterogeneity in their biologic properties and further characterization of their biochemical heterogeneity should yield important information. The present study sought to demonstrate the activity of a biochemical marker of estrogen synthesis, the aromatase enzyme, in melanoma tissue and to determine its range of activity. Initially, we validated a highly sensitive radiometric assay for aromatase by comparing it with a direct product isolation method. We detected production of 417 pmol/g protein/h of estrone and 37.3 pmol/g protein/h of estradiol by direct product isolation in a human melanoma and 398 pmol estrone/g protein/h by the radiometric assay. The activity present was blocked by similar amounts of the aromatase inhibitor, aminoglutethimide, as were necessary to block placental, breast cancer, and rat brain aromatase activity. We then assayed aromatase radiometrically in 19 human melanomas and found measurable activity ranging from 9 to 398 pmol estrone/g protein/h in 15 tissues. No relationship with the patient's age or sex was demonstrated. The activity exceeded by 2-fold that previously detected in 49 61 human breast cancers. This study identified a marker enzyme in melanoma tissue which varied by 40-fold among human tumors. Correlation of aromatase activity with prognosis and response to various types of therapy is now necessary to establish the biologic relevance of this finding.

UR - http://www.scopus.com/inward/record.url?scp=0024213543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024213543&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(88)90090-9

DO - 10.1016/0277-5379(88)90090-9

M3 - Article

C2 - 3220078

AN - SCOPUS:0024213543

VL - 24

SP - 1811

EP - 1816

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 12

ER -